Founded by a team of accomplished industry professionals who began working together in 2000, NovaQuest Capital Management is a premier biopharma and life sciences investment firm. NovaQuest pioneered a Product Finance solution for the industry, providing at-risk, nondilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, license products, and acquire accretive products or companies. NovaQuest has invested in scores of biopharmaceutical assets across therapeutic areas with a clinical success rate significantly higher than the industry average. Currently managing more than $2.2 billion in capital, NovaQuest is actively investing from the $1.2 billion Pharma Opportunities Fund V, evaluating global opportunities with financing needs that range from $30-100 million. For more information, please visit www.novaquest.com
Location: United States, North Carolina, Raleigh
Employees: 11-50
Founded date: 2010
Portfolio 17
| Date | Name | Website | Total Raised | Location |
| 27.05.2022 | TARGAN Inc... | targan.com | $35M | United Sta... |
| - | BiPar Scie... | sanofi.us | - | United Sta... |
| - | Catalyst C... | catalystcr.com | - | United Sta... |
| - | Eli Lilly ... | lilly.com | - | United Sta... |
| - | Pfizer Inc... | pfizer.com | $31B | United Sta... |
| - | Azurity Ph... | azurity.com | - | United Sta... |
| - | Hospira | hospira.com | - | United Sta... |
| - | ProStrakan... | prostrakan.com | - | - |
| - | InformedDN... | informeddna.com | - | United Sta... |
| - | Oculex Pha... | allergan.com | - | United Sta... |
Show more
Mentions in press and media 26
| Date | Title | Description |
| 07.08.2025 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) Thu, Aug 07, 2025 07:00 CET Report this content Lund, Sweden August 7, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in... |
| 17.07.2025 | Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results | Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results Thu, Jul 17, 2025 07:00 CET Report this content Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest de... |
| 08.07.2025 | Gallant Secures $18M to Transform Pet Healthcare | Gallant, an animal health biotechnology leader, secured $18 million in Series B funding. Digitalis Ventures led the round. BOLD Capital, Hill Creek Partners, and NovaQuest Capital Management also participated. This capital infusion accelera... |
| 02.07.2025 | Gallant: $18 Million Series B Raised For Ready-To-Use Stem Cell Therapies For Pets | Gallant, an animal health biotechnology company focused on developing off-the-shelf stem cell therapies for pets, announced it has closed its $18 million Series B financing. The funding round was led by Digitalis Ventures, with continued su... |
| 18.07.2022 | Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform | Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform Mon, Jul 18, 2022 21:00 CET Report this content Pro... |
| 13.05.2022 | Investors are taking a second look at the middle of America | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. JPMorgan Chase’s Jamie Dimon was in the small city of Bentonville, Ark. this week. So were (or st... |
| 29.03.2022 | Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis | Aachen, Germany, and Raleigh, North Carolina - USA, 29 March 2022 – Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (... |
| 13.01.2022 | Westcap Announces Final Close of $285 million for Fund III, the Largest Private Equity Raise by a Saskatchewan-based Fund Manager | — Westcap Mgt. Ltd. (“Westcap”), is pleased to announce the final close of Westcap MBO III Investment LP (“Fund III” or the “Limited Partnership”) of $285 million. Upon its launch in spring 2021, Fund III targeted a minimum raise of $150 mi... |
| 02.12.2021 | The Week in Agrifoodtech: Mr Yum, FJDynamics & Back to the Roots bag big fundings | This week, Aussie startup Mr Yum, which makes QR code-based ordering and payments software for hospitality companies, raised one of the Lucky Country’s biggest Series A rounds ever; while farm robotics company FJDynamics scored big money fr... |
| 30.11.2020 | Labby gets seed funding for mastitis detection technology | The global dairy industry suffers between $19.7 billion and $30 billion in annual losses thanks to mastitis, according to the University of Glasgow. For milk testing technology startup Labby, it’s not a matter of if a dairy cow will get mas... |
Show more